Abstract The receptor for advanced glycation end products (RAGE), a pattern recognition receptor, plays role in chronic inflammation. Abrogation of proinflammatory RAGE signaling by ligand binding (e.g., S100/calgranulins) to soluble decoy (sRAGE) is promising novel therapeutic avenue inflammatory diseases, such as bowel disease (IBD). However, the opportunities studying S100/calgranulin-RAGE p...
